- Home
- TGB vs RCUS Comparison
TGB vs RCUS Comparison
Compare TGB & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGB
- RCUS
- Stock Information
- Founded
- TGB 1966
- RCUS 2015
- Country
- TGB Canada
- RCUS United States
- Employees
- TGB N/A
- RCUS N/A
- Industry
- TGB Precious Metals
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- TGB Basic Materials
- RCUS Health Care
- Exchange
- TGB Nasdaq
- RCUS Nasdaq
- Market Cap
- TGB 1.1B
- RCUS 1.2B
- IPO Year
- TGB N/A
- RCUS 2018
- Fundamental
- Price
- TGB $3.93
- RCUS $16.60
- Analyst Decision
- TGB Hold
- RCUS Buy
- Analyst Count
- TGB 1
- RCUS 8
- Target Price
- TGB $5.00
- RCUS $26.00
- AVG Volume (30 Days)
- TGB 5.6M
- RCUS 1.2M
- Earning Date
- TGB 11-05-2025
- RCUS 11-05-2025
- Dividend Yield
- TGB N/A
- RCUS N/A
- EPS Growth
- TGB N/A
- RCUS N/A
- EPS
- TGB N/A
- RCUS N/A
- Revenue
- TGB $424,271,553.00
- RCUS $262,000,000.00
- Revenue This Year
- TGB $9.68
- RCUS N/A
- Revenue Next Year
- TGB $44.23
- RCUS N/A
- P/E Ratio
- TGB N/A
- RCUS N/A
- Revenue Growth
- TGB N/A
- RCUS 6.07
- 52 Week Low
- TGB $1.67
- RCUS $6.50
- 52 Week High
- TGB $4.84
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- TGB 47.18
- RCUS 70.15
- Support Level
- TGB $4.35
- RCUS $15.38
- Resistance Level
- TGB $4.72
- RCUS $17.67
- Average True Range (ATR)
- TGB 0.20
- RCUS 1.08
- MACD
- TGB -0.06
- RCUS 0.20
- Stochastic Oscillator
- TGB 2.39
- RCUS 82.34
About TGB Taseko Mines Ltd.
Taseko Mines Ltd is a Canadian mining company. It is principally engaged in the production and sale of metals, as well as related activities, including exploration and mine development, within the province of British Columbia, Canada, and the State of Arizona, the United States. The Gibraltar, Aley, New Prosperity, Yellowhead properties are located in British Columbia whereas Florence copper is in central Arizona.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.